Literature DB >> 15962273

Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis.

Pierluigi Baron1, Simona Bussini, Veronica Cardin, Massimo Corbo, Giancarlo Conti, Daniela Galimberti, Elio Scarpini, Nereo Bresolin, Stephen B Wharton, Pamela J Shaw, Vincenzo Silani.   

Abstract

The presence of activated microglia in the spinal cord of amyotrophic lateral sclerosis (ALS) patients is usually accompanied by inflammatory biochemical changes, but these are largely unexplored. Monocyte chemoattractant protein-1 (MCP-1) is critical for recruitment of inflammatory cells of monocytic lineage after inflammation or injury to the central nervous system. MCP-1 concentrations were measured by an enzyme-linked immunosorbent assay in the cerebrospinal fluid (CSF) and the serum of 27 patients with ALS and 30 patients with noninflammatory neurological diseases. In ALS, circulating MCP-1 levels were significantly increased in the serum and particularly in the CSF. Immunoreactivity for MCP-1 in ALS spinal cord was detected mostly in astrocytes but also in microglia, neurons, and within the vasculature of the cord. Our findings suggest a role for MCP-1 as an important molecular mediator of the injury response in ALS. Muscle Nerve, 2005.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15962273     DOI: 10.1002/mus.20376

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  32 in total

Review 1.  Neuronal chemokines: versatile messengers in central nervous system cell interaction.

Authors:  A H de Haas; H R J van Weering; E K de Jong; H W G M Boddeke; K P H Biber
Journal:  Mol Neurobiol       Date:  2007-07-10       Impact factor: 5.590

2.  Mutant SOD1 G93A microglia have an inflammatory phenotype and elevated production of MCP-1.

Authors:  Siranush A Sargsyan; Daniel J Blackburn; Siân C Barber; Peter N Monk; Pamela J Shaw
Journal:  Neuroreport       Date:  2009-10-28       Impact factor: 1.837

Review 3.  Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease.

Authors:  Christi Kolarcik; Robert Bowser
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

Review 4.  Peripheral inflammation in neurodegeneration.

Authors:  Ulrike Träger; Sarah J Tabrizi
Journal:  J Mol Med (Berl)       Date:  2013-04-02       Impact factor: 4.599

5.  Gene expression profiling in peripheral blood mononuclear cells from patients with sporadic amyotrophic lateral sclerosis (sALS).

Authors:  Rongzhen Zhang; Kenneth G Hadlock; Hien Do; Stephanie Yu; Ronald Honrada; Stacey Champion; Dallas Forshew; Catherine Madison; Jonathan Katz; Robert G Miller; Michael S McGrath
Journal:  J Neuroimmunol       Date:  2010-09-29       Impact factor: 3.478

6.  Immunological aspects in amyotrophic lateral sclerosis.

Authors:  Maria Carolina O Rodrigues; Júlio C Voltarelli; Paul R Sanberg; Cesario V Borlongan; Svitlana Garbuzova-Davis
Journal:  Transl Stroke Res       Date:  2012-05-03       Impact factor: 6.829

7.  Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-3 through NFkB and MAPK dependent pathways in rat astrocytes [corrected].

Authors:  Wendy L Thompson; Linda J Van Eldik
Journal:  Brain Res       Date:  2009-07-03       Impact factor: 3.252

Review 8.  Biomarkers in amyotrophic lateral sclerosis: facts and future horizons.

Authors:  Pierre-François Pradat; Michel Dib
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 9.  Microglia in ALS: the good, the bad, and the resting.

Authors:  Jenny S Henkel; David R Beers; Weihua Zhao; Stanley H Appel
Journal:  J Neuroimmune Pharmacol       Date:  2009-12       Impact factor: 4.147

10.  Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS).

Authors:  Rongzhen Zhang; Robert G Miller; Ron Gascon; Stacey Champion; Jonathan Katz; Mariselle Lancero; Amy Narvaez; Ronald Honrada; David Ruvalcaba; Michael S McGrath
Journal:  J Neuroimmunol       Date:  2008-11-14       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.